VASOVIST SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

GADOFOSVESET TRISODIUM

Disponibbli minn:

BAYER INC

Kodiċi ATC:

V08CA11

INN (Isem Internazzjonali):

GADOFOSVESET

Dożaġġ:

244MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

GADOFOSVESET TRISODIUM 244MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

10ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

OTHER DIAGNOSTIC AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0151671001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2009-08-06

Karatteristiċi tal-prodott

_ _
_ _
Page 1 of 46
PRODUCT MONOGRAPH
VASOVIST
®
gadofosveset trisodium injection
244 mg/mL (0.25mmol/mL)
For intravenous use
Intravenous contrast enhancement agent
for magnetic resonance imaging (MRI)
Bayer Inc.
77 Belfield Road
Toronto, ON
M9W 1G6
Canada
www.bayer.ca
Submission Control Number: 121901
©2008, Bayer Inc.
Date of Revision:
July 16, 2008
®Vasovist is a registered trademark, used under license by Bayer Inc.
_ _
_ _
Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND
ADMINISTRATION..............................................................................18
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND
STABILITY..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL
INFORMATION..........................................................................24
CLINICAL
TRIALS............................................